Market Research Logo

Dementia Drugs Market - Global Forecast to 2026

Dementia Drugs Market - Global Forecast to 2026

Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently, there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in pipeline, which are expected to be launched in the near future, in turn propelling growth of the dementia drugs market.
Market Dynamics
Increasing aging population along with its associated complications is the major driving factor for growth of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14 million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2017, around 47 million people suffer from dementia and around 10 million new cases are reported annually. Increasing incidence of dementia coupled with growing demand for therapy is expected to favor growth of the dementia drugs market in the near future. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020, and around 900,000 by 2050. Moreover, the National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to prioritize and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment, and care for dementia patients.
Key features of the study:

  • This report provides in-depth analysis of the dementia drugs market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global dementia drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, market expansion, and marketing tactics
  • The global dementia drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for dementia drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
  • Global Dementia Drugs Market, By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • Global Dementia Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Global Dementia Drugs Market, By Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Africa
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • By Drug Class:
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitors
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Company Profiles
  • Eisai, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Janssen Pharmaceuticals, Inc.
  • Biogen Pharmaceuticals
  • Forest Laboratories, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi S.A.
  • AstraZeneca GmbH
  • Hoffmann-La Roche
  • Merck & Co., Inc.
  • Valeant Pharmaceutical International
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Pipeline Analysis
Epidemiology
Historical Overview
Overview of Sub-classes of Drugs
Revenue Potential of Drugs
PORTER’S Five Forces
PEST Analysis
4. Global Dementia Drugs Market, By Drug Class, 2016–2026, (US$ Million)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
MAO Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
Cholinesterase Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
Glutamate Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
5. Global Dementia Drugs Market, By Distribution Channel, 2016–2026, (US$ Million)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
6. Global Dementia Drugs Market, By Regions, 2016–2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2017 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2017–2026
Regional Trends
North America
Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)
Northern Africa
Central Africa
South Africa
Middle East
Market Size and Forecast, By Drug Class, 2016–2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2016–2026, (US$ Million)
Market Size and Forecast, By Country, 2016–2026, (US$ Million)
GCC Countries
Israel
Rest of Middle East
7. Competitive Landscape
Heat Map Analysis
Company Profiles
Eisai, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Janssen Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Biogen Pharmaceuticals
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Forest Laboratories, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Eli Lilly and Company
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Novartis AG
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Sanofi S.A.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca GmbH
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
F. Hoffmann-La Roche
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co., Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Valeant Pharmaceutical International
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Pfizer Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Teva Pharmaceuticals Industries Ltd
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Analyst Views
8. Section
References
Research Methodology
About Us and Sales Contact
*Browse 25 market data tables and 44 figures on "Dementia Drugs Market” - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report